Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

Nestled at the foot of the legendary Matterhorn, this picturesque ... week could be enough to lower your risk of dying from heart disease Anthony Albanese declared winner of first federal election ...

Located at the foot of the Matterhorn, this charming alpine village ... week could be enough to lower your risk of dying from heart disease Recent Study Challenges When European Skin Became ...

Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

AstraZeneca’s Imfinzi receives US FDA approval for patients with muscle-invasive bladder cancer: Cambridge, UK Tuesday, April 1, 2025, 10:00 Hrs [IST] AstraZeneca’s Imfinzi (d ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Imfinzi has also shown to reduce the risk of disease progression or death by ... The company also reported positive results from its MATTERHORN Phase III trial, where Imfinzi (durvalumab) combined ...

Moving on to Slide 18, in late 2023, Subgroup analysis from the Phase 3 MATTERHORN study of roxadustat ... and oncology related diseases has the potential to create tremendous value, for patients ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD ... endpoint of event-free survival in the MATTERHORN Phase III trial in resectable gastric ...